Dr. David Harris, a board-certified urologist at Advanced Urology Institute, discusses how they are revolutionizing risk management in prostate cancer.



At Advanced Urology Institute, we understand the importance of stratifying risk accurately. When a patient is diagnosed with prostate cancer, we have a range of tests available that utilize genomic testing. By analyzing the patient's cancer tissue, we can accurately predict the aggressiveness of the cancer.


For patients who are older or have additional medical conditions and present with low-risk cancer, our approach is to monitor the cancer closely rather than pursuing aggressive treatment. This personalized approach allows us to ensure the patient's well-being without unnecessary intervention.


However, for patients with intermediate-risk cancer, determining the appropriate level of treatment can be challenging. That's where genomic testing becomes crucial. By utilizing the genomic testing results, we can accurately assess the aggressiveness of the cancer and make informed decisions about active treatment or careful monitoring.


Furthermore, we also employ genomic testing when a biopsy yields negative results but there are still concerns. By analyzing negative biopsy tissue, we can predict the likelihood of a positive result in subsequent biopsies. This proactive approach helps us identify potential risks and provide appropriate recommendations for further investigation.


At Advanced Urology Institute, our commitment is to optimize patient care through advanced diagnostic tools and personalized treatment plans. Stay tuned to our channel for more valuable insights on urological health.


#AdvancedUrologyInstitute #ProstateCancer #GenomicTesting


---
Transcription:
My name is David Harris, and I'm a board-certified urologist with Advanced Urology Institute. It really is, and this is one of the ways that we are stratifying risk. We're better managing risk. So if I have a patient who's been found to have prostate cancer, we have several tests available that we can employ where the patient's cancer tissue is sent, and we're doing genomic testing. And with those tests, we're able to predict the aggressiveness of the cancer. So if we're having a man who's getting a bit older, and he has some medical problems, and we find that it is a low-risk cancer, we would be much more comfortable just following that patient. On the other hand, if we get a patient where it is more an intermediate-risk cancer, and we're not quite sure how aggressive to be with treatment, if we get the genomic testing and it indicates that that's a guy with a more aggressive cancer, then we may keep him on the right track and make sure that we're treating that actively rather than perhaps just watching. We also have genomic testing we can do if a biopsy is negative, but we're still concerned we can send negative biopsy tissue, which can give us a prediction if another biopsy would be positive. So it is very much helping us identify risk.


---


Advanced Urology Institute
www.advancedurologyinstitute.com


Advanced Urology Institute is the largest urology practice in Florida. We are dedicated to improving the lives of our patients by providing excellent Patient-Centered Care.


Schedule a visit: https://www.advancedurologyinstitute....




Like us on Facebook:   / advanced-urology-institute-1667209733546925  
Follow us on Twitter:   / advancedurology  
Follow us on Instagram:   / advancedurologyinstitute  
Pin us on Pinterest:   / advancedurology  


Urology, Urologist, Florida, FL